APG Stock Recent News

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced today that it intends to release its financial results for the three and nine months ended September 30, 2024, before the market opens on Thursday, October 31, 2024. Third Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, October 31, 2024. Participants on the call will include Russell A. Becker, Preside.

APi Group Corporation's earnings are set to grow in Q3 and Q4 2024, despite a recent decline in share price, presenting a Strong Buy opportunity. The company's 13/60/80 framework aims to boost adjusted EBITDA margins, recurring revenue, and free cash flow conversion. APi's aggressive acquisition strategy, including the recent purchase of Elevated Facility Services Group, supports its growth and expansion goals.

PHILADELPHIA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Doral Renewables LLC (”Doral Renewables” or “the Company”), a leading U.S. developer, owner, and operator of renewable energy and storage projects, announced today the closing of a $400 million minority equity investment by Dutch pension APG on behalf of the largest Dutch pension fund ABP. The investment by and partnership with APG will accelerate the development and construction of Doral Renewables' energy pipeline. As part of the transaction, APG will also provide its pro rata share of corporate credit support and funding for the Company's business up to an additional $185 million of capital over time.

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG990, a novel, subcutaneous (SQ) half-life extended monoclonal antibody targeting OX40L, which is being developed initially as a treatment for people living with AD.

Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024

- Over 325 Diesel Frac Engines/Pumps Converted to APG's Dual Fuel Technology to Date - ALGONA, IA / ACCESSWIRE / August 6, 2024 / American Power Group Corporation ("APG") (OTC Pink:APGI) announced today that it has received approximately $2.2 million of follow-on orders since October 1st from its network of stationary certified dealer/installers with approximately $800,000 received and to be shipped in the September 4th fiscal quarter. Fiscal 2024 YTD revenue is approximately $2.9 million which is over 230% higher than all of fiscal 2023 and attributable to stronger dual fuel stationary conversion revenue.

APi Group Corporation (NYSE:APG ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Adam Fee - Vice President, Investor Relations Russell Becker - President and Chief Executive Officer Kevin Krumm - Executive Vice President and Chief Financial Officer Conference Call Participants Kathryn Thompson - Thompson Research Group Andy Kaplowitz - Citigroup Jack Cauchi - Barclays Jon Tanwanteng - CJS Securities Stephanie Moore - Jefferies Josh Chan - UBS Charles Tusa - JPMorgan David Paige - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the APi Group's Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note that this call is being recorded.

APi (APG) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.41 per share a year ago.

Greystone Capital managed separate accounts with returns ranging from +4.3% to +7.1% in Q2 2024, with a median return of +6.0%. Second quarter and year-to-date results compare both unfavorably and favorably to the S&P 500 and Russell 2000 returns of +4.3% and -3.3% during the quarter and +15.2% and +1.7% year-to-date. It's worth repeating that there are things to invest in outside of both the Magnificent 7 and major indices, making now an ideal time to allocate to a strategy like ours.

Investors with an interest in Business - Services stocks have likely encountered both APi (APG) and UL Solutions Inc. (ULS). But which of these two companies is the best option for those looking for undervalued stocks?